There was a significant test for trend across all PPI
dose categories, including nonusers (P < .001 for trend), although
not among analyses confined only to different doses
among users of PPIs, using the less than 0.75 pills/d category
as the reference category (P = .22). Similar results were found
for H2RA use, with a significant test for trend across all categories
of H2RA use (P < .001 for trend), although not among
only users of H2RAs, using the less than 0.75 pills/d category
as the reference category (P = .84 for trend)